

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 30.07.2020

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1), 52 (3), 52(4), 52(5), 52 (7), 54 (2), 56 (1)(d) Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The annual financial results of the Company for the financial year ended 31<sup>st</sup> March, 2020 along with the Annual Audit Report for that period issued by the Statutory Auditors under SEBI (LODR), 2015.
- ii. Declaration by Mr. Ganesh Prasad Gupta, Compliance Officer pursuant to Regulation 52 (3)(a) of SEBI (LODR), 2015.
- iii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015 (Annexure 1).
- iv. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015.
- v. A statement pursuant to Regulation 52(7) of SEBI (LODR), 2015.
- vi. A disclosure under Regulation 54(2) of SEBI (LODR), 2015.
- vii. A Certificate under Regulation 56 (1)(d) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

  
Ganesh Prasad Gupta  
Company Secretary and Compliance Officer  
Membership no. A33925





## INDEPENDENT AUDITORS' REPORT

To  
The Members of  
**Genlink Pharma Solutions Private Limited**  
**Mumbai**

### Report on the audit of the financial statements

#### Opinion

We have audited the accompanying financial statements of **Genlink Pharma Solutions Private Limited** ("the Company"), which comprise of the Balance Sheet as at March 31, 2020, the Statement of Profit and Loss statement for the year then ended, Cash Flow statement and Notes to the Financial Statements, including a summary of Significant Accounting Policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, its profits for the year ended on that date.

#### Basis for opinion

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.



# Shankarlal Jain & Associates LLP

## Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

### Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

### Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.


Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

### Management's responsibility for the financial statements

The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the



# Shankarlal Jain & Associates LLP

## Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The boards of directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing



# Shankarlal Jain & Associates LLP

## Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : [info@sljainindia.com](mailto:info@sljainindia.com)

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : [www.sljainindia.com](http://www.sljainindia.com)

our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.





### Report on other legal and regulatory requirements

1) As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The balance sheet, the statement of profit and loss, and the cash flow statement dealt with by this report are in agreement with the books of account;
- (d) In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;
- (e) On the basis of the written representations received from the directors as on March 31, 2020 taken on record by the board of directors, none of the directors is disqualified as on March 31, 2020 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls – refer to our separate Report in "**Annexure A**" to Auditors' Report; and
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;
  - i. The Company does not have any pending litigations which would impact its financial position;
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



# Shankarlal Jain & Associates LLP

## Chartered Accountants




12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

- 2) As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure B" statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable

For SHANKARLAL JAIN & ASSOCIATES LLP  
Chartered Accountants  
Firm Registration No. 109901W/W100082



A handwritten signature in black ink, appearing to read "Satish Jain".

Satish Jain  
Partner  
Membership No. 048874  
UDIN : 20048874AAAABR9354

Place: Mumbai

Date: 22<sup>nd</sup> June, 2020



### **Annexure - A to the Independent Auditors' Report**

(Referred to in paragraph 1(A)(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

#### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED** ("the Company") as of 31st March 2020 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.



# Shankarlal Jain & Associates LLP

## Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.



Place: Mumbai

Date: 22<sup>nd</sup> June, 2020

For SHANKARLAL JAIN & ASSOCIATES LLP  
Chartered Accountants  
Firm Registration No. 109901W/W100082

Satish Jain  
Partner

Membership No. 048874

UDIN : 20048874AAAABR9354



### GENLINK PHARMA SOLUTIONS PRIVATE LIMITED FOR THE YEAR ENDED 31ST MARCH, 2020

#### Annexure - B to the Independent Auditors' Report

1. a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.  
b) The fixed assets of the company have been physically verified during the year by the management and no material discrepancies between the book records and the physical inventory have been noticed.  
c) The title deeds of immovable properties held as fixed assets is in the name of the company.
2. The Company has no inventory during the period. Hence provisions of clause 3(ii) of the Companies (Auditors Report) Order 2016 are not applicable to the Company.
3. As per the information and explanations given to us, the company has not granted unsecured loans to a company covered in the register maintained under Section 189 of the Companies Act. Hence relevant clause is not applicable.
4. In our opinion and according to information and explanation given to us, in respect of loans, investments, guarantees and security, the Company has complied with the provisions of sections 185 and section 186 of the Companies Act, 2013.
5. As per the information and explanations given to us, the company has not accepted deposits from the public within the meanings of Sections 73 to 76 of the Companies Act and the rules framed there under.
6. In our opinion and according to information and explanations given to us, the Central Government has not prescribed the maintenance of costs records under section 148 of the Companies Act, 2013.
7. a) According to the information and explanation given to us and based on the books and records examined by us, Investor Education and Protection Fund, Income Tax, Goods and Services Tax, Cess and other statutory dues, wherever applicable, have been generally deposited regularly during the year with appropriate authorities.  
b) According to the information and explanation given to us and based on the books and records examined by us, there are no dues of Income Tax, Goods & Services Tax, Cess and other statutory dues, wherever applicable, which have not been deposited on account of any dispute.
8. In our opinion the company has not defaulted in repayment of dues to a financial institution or Bank during the year.



# Shankarlal Jain & Associates LLP

## Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

9. As per the information and explanation given to us the company has not raised money by way of public offer. The company has utilized the term loan for the purpose for which it was taken by the company and has not committed any default
10. According to the information and explanation given to us, no fraud on or by the company has been noticed or reported during the year.
11. The provision of managerial remuneration section 197 read with Schedule V to the Companies Act, 2013 is not applicable.
12. As per the information and explanation given to us the company is not a nidhi company hence provisions of Nidhi Rules, 2014 are not applicable.
13. All the transactions entered into with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013.
14. The company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review.
15. The company has not entered into any non-cash transactions with directors or persons connected with him.
16. In our opinion the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934

For SHANKARLAL JAIN & ASSOCIATES LLP  
Chartered Accountants  
Firm Registration No. 109901W/W100082



Satish Jain

Partner

Membership No. 048874

UDIN : 20048874AAAABR9354

Place: Mumbai

Date: 22<sup>nd</sup> June, 2020

**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
 (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)  
 STANDALONE BALANCE SHEET AS AT 31st March 2020

Particulars	Note No.	As at 31 March 2020 (Audited)	( Amount in INR) As at 31 March 2019 (Audited)
<b>I. ASSETS</b>			
<b>1 Non-current assets</b>			
(a) Property, Plant & Equipment	2	29,920,858	30,433,702
(a) Non-current investments	3	248,995,479	248,995,479
<b>2 Current assets</b>			
(a) Trade receivables	4	653,950	1,440,400
(a) Cash and cash equivalents	5	2,563	6,601
(b) Other current assets	6	324,500	34,168
<b>TOTAL</b>		<b>279,897,349</b>	<b>280,910,350</b>
<b>II. EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
(a) Share capital	7	100,000	100,000
(b) Other Equity	8	2,497,322	2,127,852
<b>2 Non-current liabilities</b>			
(a) Financial Liabilities			
(i) Long-term borrowings	9	271,889,120	272,948,634
<b>3 Current liabilities</b>			
(a) Financial Liabilities			
(i) Other financial liabilities	10	5,235,907	5,155,864
(b) Current tax liabilities & Provisions	11	175,000	578,000
<b>TOTAL</b>		<b>279,897,349</b>	<b>280,910,350</b>

For Shankarlal Jain & Associates LLP  
 Chartered Accountants  
 Registration No : 109901W/W100082

*Jain S.*

Satish Jain  
 Partner

Membership No. : 048874  
 Mumbai

Date : 22 JUN 2020

For Genlink Pharma Solutions Private limited

*Anand Shah* *Susheel Koul*

Anand Shah  
 Chairman  
 DIN: - 00597145  
 Navi Mumbai

Date : 22-JUNE-2020

Susheel Koul  
 Managing Director  
 DIN: - 00925887  
 Navi Mumbai



**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)  
**STANDALONE BALANCE SHEET AS AT 31st March 2020**

( Amount in INR)

Particulars	Refer Note No	As at 31 March 2020 (Audited)	As at 31 March 2019 (Audited)
<b>I REVENUE</b>			
Revenue from operations	12	3,960,000	7,870,000
<b>Total Revenue</b>		<b>3,960,000</b>	<b>7,870,000</b>
<b>II EXPENSES</b>			
Finance costs	13	2,291,655	797,338
Depreciation and amortisation expenses	14	512,845	254,306
Other expenses	15	701,117	700,055
<b>Total expenses</b>		<b>3,505,617</b>	<b>1,751,699</b>
<b>III Profit/(Loss) before tax (I-II)</b>		<b>454,384</b>	<b>6,118,301</b>
<b>IV Tax expense</b>			
Current tax		84,000	1,220,000
(Excess)/Short Provision for Tax		913	521
<b>V Profit/(Loss) after tax (III-IV)</b>		<b>369,471</b>	<b>4,897,780</b>
<b>VI Earnings Per Share</b>			
-Basic & Diluted		<b>36.95</b>	<b>489.78</b>

For Shankarlal Jain & Associates LLP  
Chartered Accountants  
Registration No : 109901W/W100082

*Jain S.*

Satish Jain  
Partner  
Membership No. : 048874  
Mumbai  
Date : 22 JUN 2020

For Genlink Pharma Solutions Private Limited

*Anand Shah*      *Susheel Koul*

Anand Shah  
Chairman  
DIN: - 00597145  
Navi Mumbai

Susheel Koul  
Managing Director  
DIN: - 00925887  
Navi Mumbai

Date : 22-JUNE-2020




**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
(Formerly known as Genlink Pharma Investments Private Limited)

CIN: U74110MH2016PTC280765

Reg Off. : 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai, 400705, Maharashtra, India.  
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email: genlinkinfo@gmail.com Website: www.genlinkpharma.com

**Standalone Audited Financial Results for the year ended 31st March, 2020**

(Rs. In Lacs)

Sr. No.	Particulars	Year to date figures for Current	Previous accounting year
		Period ended 31/03/2020	ended 31/03/2019
		Audited	Audited
1. (a)	Net Sales/ Income from Operations	39.60	78.70
(b)	Other Operating Income	-	-
2	<b>Expenditure</b>	<b>35.05617</b>	<b>17.52</b>
a.	Increase / decrease in Stock in trade and work in progress	-	-
b.	Consumption of raw materials	-	-
c.	Purchase of traded goods	-	-
d.	Employees Cost	-	-
e.	Depreciation	5.12845	2.54
f.	Other Expenditure	7.01117	7.00055
g.	<b>Total</b>	<b>12.13962</b>	<b>9.54</b>
h	Finance Costs	22.91655	7.97338
3	Profit from Operations other Income, Interest and Exceptional Items (1-2)	4.54	61.18
4	Other Income	-	-
5	Profit before Interest and Exceptional Items (3+4)	4.54	61.18
6	Interest	-	-
7	Exceptional Items	-	-
8	Profit (+)/ Loss(-) from Ordinary Activities before tax (3)-(4+5+6)	4.54	61.18
9	Tax Expense	0.84913	12.20521
10	Net Profit (+)/Loss(-) from Ordinary Activities after tax(7-8)	4.54	61.18
11	Extraordinary Items (net of tax expense Rs. __)	-	-
12	Net Profit (+)/Loss(-) for the Period (9-10)	3.69087	48.97479
13	Paid up Equity Share Capital (Face Value of the Share shall be indicated)	10	10
14	Paid up Debt Capital	2500	2500
15	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	24.97322	21.27852
16	Debenture Redemption Reserve	-	-
17	Earnings per share (EPS)	36.95	489.78
18	Debt Equity Ratio	104.99	122.91
19	Debt Service Coverage Ratio	0.89	4.17
20	Interest Service Coverage Ratio	1.20	8.92
<b>For Genlink Pharma Solutions Private Limited</b>			
		 Sd/- <b>Susheel Koul</b> Managing Director DIN: 00925887	
Date: 22 June, 2020			
Place: Navi Mumbai			

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 22.06.2020

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Subject: Declaration pursuant to Regulation 52(3)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scrip Code: Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

Pursuant to Regulation 52(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, I, Ganesh Prasad Gupta, Company Secretary and Compliance Officer of Genlink Pharma Solutions Private Limited (Formerly Known as Genlink Pharma Investments Private Limited) (CIN: U74110MH2016PTC280765), having its Registered Office at Office No - 1701, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400705, Maharashtra, India, do hereby declare that, the Statutory Auditors of the Company, Shankarlal Jain & Associates LLP, Chartered Accountants (FRN 109901W/W100082) have issued an Audit Report with an unmodified opinion on the standalone Audited Financial Results of the Company for the year ended March 31, 2020.

Kindly take this declaration on record.

Yours faithfully,

For Genlink Pharma Solutions Private Limited

  
Ganesh Prasad Gupta  
Company Secretary & Compliance Officer  
Membership no. A33925



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

With reference to Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find disclosure as under for the annual period ended as on 31<sup>st</sup> March, 2020

- 1. Credit rating** - The Company's NCDs have been rated as "ACUITE B " by Acuite Ratings & Research Limited (formerly known as SMERA Ratings Limited). There has been change in the credit rating of the Company from "ACUITE BB-" to ACUITE B ".
- 2. Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
- 3. Debt-equity ratio** - 104.99 times
- 4. Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
- 5. Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
- 6. Next due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence no due date is applicable.
- 7. Debt service coverage ratio** - 0.89 times
- 8. Interest service coverage ratio** - 1.20 times
- 9. Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares.
- 10. Capital redemption reserve/debenture redemption reserve** - 0
- 11. Net worth** - The net worth of the Company is - Rs 25.97 lakhs
- 12. Net profit after tax**  
Net profit after tax of the Company is Rs 3,69,471/-
- 13. Earnings per share**  
Earnings per share of the Company is Rs 36.95/-

For Genlink Pharma Solutions Private Limited

  
  
Ganeshprasad Gupta  
Company Secretary and Compliance Officer  
Membership no. A33925

**Date:** 30.07.2020

**To**  
**Board of Directors,**  
**Genlink Pharma Solutions Private Limited**  
**Address:** 1701, 17<sup>th</sup> Floor, Kesar Solitaire,  
Plot No. 5, Sector 19,  
Sanpada, Navi Mumbai - 400 705,  
Maharashtra, India

**Ref:** Scrip code 956084 and ISIN INE988W07019

**Subject:** Certificate of Debenture Trustee for half year ended 31<sup>st</sup> March, 2020.

In compliance of the requirement of Chapter V, Regulation 52(4) and 52(5) of the Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 it is certified as under:

We, Vistra ITCL (India) Limited are acting as a Debenture Trustee for the debenture programme of Secured Redeemable, Listed, Non-Convertible Debenture issue aggregating to Rs 25,00,00,000/- (Rupees Twenty Five Crores Only) of Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited), "the Company"

With reference to the above, we have received the following documents and noted its contents:

1. Audited financial results for the year ended 31<sup>st</sup> March, 2020 along with Audit Report issued by the Statutory Auditor for that period.
2. Disclosure pursuant to Regulation 52 (4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended 31<sup>st</sup> March, 2020.

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You.  
Yours sincerely,  
**For Vistra ITCL (India) Limited**



**Authorized signatory**  
**Place:** Mumbai

Registered office:

The IL&FS Financial Centre,  
Plot C- 22, G Block, 7th Floor  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400051

Tel +91 22 2659 3535  
Fax: +912226533297  
**Limited**  
Email: [mumbai@vistra.com](mailto:mumbai@vistra.com)  
[www.vistraitcl.com](http://www.vistraitcl.com)

**Vistra ITCL (India)**

Corporate Identity Number (CIN):U66020MH1995PLC095507

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the year ended 31<sup>st</sup> March, 2020, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Private Limited



Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
Membership no. A33925

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE UNDER REGULATION 54 OF SEBI (LODR), 2015

We hereby state that the Company maintains as on annual period ended 31<sup>st</sup> March, 2020 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 563,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Genlink Pharma Solutions Private Limited.
2. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

For Genlink Pharma Solutions Private Limited



Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
Membership no. A33925



# Shankarlal Jain & Associates LLP

## Chartered Accountants

12, Engineer Building, 265 Princess Street, Mumbai – 400 002. Phone: 22036623, 22065739

Fax: 91-22-22086269 E-mail: [info@sljainindia.com](mailto:info@sljainindia.com)

### TO WHOMSOEVER IT MAY CONCERN

This is to certify that **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN U74110MH2016PTC280765) having its registered office at 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai - 400705 has Asset Cover Ratio of **1.13 times** & Debt Equity Ratio of **104.18 times** as on quarter ended March 31st, 2020 based on the details and documents provided to us which is tabulated herein below:

Sr. No	Particulars	Unit	Amount (Rs)
a)	Non-Convertible Debentures (NCD) value	Rs. Lacs	2,500/-
b)	Number of shares of Enaltec Labs Pvt. Ltd. pledged	No.	5,75,343
c)	Valuation (As per valuation report dated 04th February, 2020, Enaltec Labs Pvt. Ltd. issued by registered valuer Mr. Charudutt Marathe and which is accepted as it is)	Rs./Share	490.00
d)	Value of shares pledged ( Rs. 490.00 * 5,75,343 shares )	Rs. Lacs	2,819/-
e)	<b>Security Cover</b> (Rs Lacs 2,819/Rs. Lacs 2,500)	Ratio	<b>1.13</b>

Note: Shares include 11,846 shares pledged by Promoters (Mr. Anand Shah: 5,923 shares and Mr. Susheel Koul: 5,923 shares)

**Debt Equity Ratio** : Total Debt / Total Equity i.e. Rs. 27,23,12,196/ Rs. 26,13,933= **104.18 times**.

Since the Company has issued Zero Coupon Debentures, Debt Service Coverage Ratio and Interest Service Coverage Ratio are not applicable in the above mentioned NCD and no other borrowings are considered in calculating the said mentioned ratios.

---

**Branch Office:** Shopper's Point, 5th Floor, H.B.Road, Fancy Bazar, Guwahati-781001.

**Contact Partner:** Bineet Bagaria, B.Com, A.C.A. Phone: 0361-543445.

# Shankarlal Jain & Associates LLP

## Chartered Accountants

12, Engineer Building, 265 Princess Street, Mumbai – 400 002. Phone: 22036623, 22065739


Fax: 91-22-22086269 E-mail: [info@sljainindia.com](mailto:info@sljainindia.com)

The above mentioned Company has utilized Debenture Subscription Receipts of Rs. 25,00,00,000/- (Rs Twenty Five Crores) for purchase of equity shares (5,63,497 equity shares) of Enaltec Labs Private Limited.

The above mentioned Company has not transferred any amount to Debenture Redemption Reserve as on period ended March 31st, 2020.

The above has been verified from the details and documents produced before us and is subject to audit.

FOR SHANKARLAL JAIN & ASSOCIATES LLP,  
CHARTERED ACCOUNTANTS  
FIRM REG NO: - 109901W/W100082



Place: Mumbai  
Date: 30/05/2020

Vishal Amratlal Patel  
PARTNER  
Membership No.: 114932  
UDIN : 20114932AAAAAX9088